Home Up Feedback Contents Search Contacts Publications FAQ Support About Us

Adverse effects in Humans

                                     

Home
Up
News
Products
Consulting
Request Info

 

 

 

 

 

 

 

 

 

  Adverse effects in Humans

bulletMaximum Recommended Daily Dose (mg/kg-bw/day)
bulletHepatobiliary adverse effects NEW!!!
bulletRenal and Urinary Tract adverse effects  NEW!!!
bulletCardiac adverse effects  NEW!!!

 

Maximum Recommended Daily Dose (mg/kg-bw/day)

Module ID  Description # of Compounds
A73 FDA MRTD humans       1169

Hepatobiliary

Module ID  Description # of Compounds

A10

FDA human acute liver damage, control

1608*
A11

FDA human acute liver damage, part A

457*

A12

FDA human acute liver damage, part B

457*

A13

FDA human acute liver damage, part C

457*

A14

FDA human acute liver damage, part D

457*

A15

FDA human acute liver damage, part E

456*

A17

FDA human liver enzyme release, control

1606*

A18

FDA human liver enzyme release, part A

381*

A19

FDA human liver enzyme release, part B

381*

A20

FDA human liver enzyme release, part C

381*

A21

FDA human liver enzyme release, part D

381*

A22

FDA human liver enzyme release, part E

381*

A23

FDA human liver enzyme release, part F

381*

A25

FDA human liver jaundice, control

1608*

A26

FDA human liver jaundice, part A

581*

A27

FDA human liver jaundice, part B

581*

A28

FDA human liver jaundice, part C

580*

A29

FDA human liver jaundice, part D

580*

A31

FDA human gall bladder disorders, control

1056*

A32

FDA human gall bladder disorders, part A

384*

A33

FDA human gall bladder disorders, part B

384*

A34

FDA human gall bladder disorders, part C

384*

A35

FDA human gall bladder disorders, part D

384*

A37

FDA human bile duct disorders, control

1044*

A38

FDA human bile duct disorders, part A

251*

A39

FDA human bile duct disorders, part B

251*

A40

FDA human bile duct disorders, part C

251*

A41

FDA human bile duct disorders, part D

251*

A42

FDA human bile duct disorders, part E

250*

A43

FDA human bile duct disorders, part F

250*

* - New in 2008

Renal and Urinary Tract

Module ID  Description # of Compounds

A10

FDA human renal disorder, control

1595*
A11

FDA human renal disorder, part A

435*

A12

FDA human renal disorder, part B

434*

A13

FDA human renal disorder, part C

434*

A14

FDA human renal disorder, part D

434*

A15

FDA human renal disorder, part E

434*

A17

FDA Human nephropathy disorders, control

1595*

A18

FDA Human nephropathy disorders, part A

484*

A19

FDA Human nephropathy disorders, part B

484*

A20

FDA Human nephropathy disorders, part C

484*

A21

FDA Human nephropathy disorders, part D

484*

A22

FDA Human nephropathy disorders, part E

483*

A24

FDA Human kidney function tests, control

1595*

A25

FDA Human kidney function tests, part A

578*

 A26

FDA Human kidney function tests, part B

578*

A27

FDA Human kidney function tests, part C

578*

A28

FDA Human kidney function tests, part D

578*

A30

FDA Human blood in urine disorders, control

1595*

A31

FDA Human blood in urine disorders, part A

404*

A32

FDA Human blood in urine disorders, part B

404*

A33

FDA Human blood in urine disorders, part C

403*

A34

FDA Human blood in urine disorders, part D

403*

A35

FDA Human blood in urine disorders, part E

403*

A36

FDA Human blood in urine disorders, part F

403*

A38

FDA Human urolithiasis disorders, control

1595*

A39

FDA Human urolithiasis disorders, part A

387*

A40

FDA Human urolithiasis disorders, part B

387*

A41

FDA Human urolithiasis disorders, part C

387*

A42

FDA Human urolithiasis disorders, part D

387*

A43

FDA Human urolithiasis disorders, part E

386*

A44

FDA Human urolithiasis disorders, part F

386*

A46

FDA Human bladder disorders, control

1595*

A47

FDA Human bladder disorders, part A

579*

A48

FDA Human bladder disorders, part B

579*
 A49

FDA Human bladder disorders, part C

579*

A50

FDA Human bladder disorders, part D

578*

* - New in 2008

Cardiac (to be released by soon)

Module ID  Description # of Compounds

A08

FDA human cardiac conduction disorders, control

1632*

A09

FDA human cardiac conduction disorders, part A

336*

A10

FDA human cardiac conduction disorders, part B

336*

A11

FDA human cardiac conduction disorders, part C

336*

A12

FDA human cardiac conduction disorders, part D

336*

A13

FDA human cardiac conduction disorders, part E

336*

A14

FDA human cardiac conduction disorders, part F

336*

A15

FDA human cardiac conduction disorders, part G

336*

A29

FDA human cardiac coronary artery dissorder, control

1632*

A30

FDA human cardiac coronary artery dissorder, part A

587*

A31

FDA human cardiac coronary artery dissorder, part B

587*

A32

FDA human cardiac coronary artery dissorder, part C

586*

A33

FDA human cardiac coronary artery dissorder, part D

586*

A46

FDA human cardiac electrocardiogram dissorders, control

1632*

A47

FDA human cardiac electrocardiogram dissorders, part A

416*

A48

FDA human cardiac electrocardiogram dissorders, part B

416*

A49

FDA human cardiac electrocardiogram dissorders, part C

415*

A50

FDA human cardiac electrocardiogram dissorders, part D

415*

A51

FDA human cardiac electrocardiogram dissorders, part E

415*

A52

FDA human cardiac electrocardiogram dissorders, part F

415*

A66

FDA human cardiac heart failure disorders, control

1632*

A67

FDA human cardiac heart failure disorders, part A

491*

A68

FDA human cardiac heart failure disorders, part B

491*

A69

FDA human cardiac heart failure disorders, part C

490*

A70

FDA human cardiac heart failure disorders, part D

490*

A71

FDA human cardiac heart failure disorders, part E

490*

A87

FDA human cardiac myocardial disorders, control

1632*

A88

FDA human cardiac myocardial disorders, part A

289*

A89

FDA human cardiac myocardial disorders, part B

289*

A90

FDA human cardiac myocardial disorders, part C

289*

A91

FDA human cardiac myocardial disorders, part D

289*

A92

FDA human cardiac myocardial disorders, part E

289*

A93

FDA human cardiac myocardial disorders, part F

289*

A94

FDA human cardiac myocardial disorders, part G

289*

A95

FDA human cardiac myocardial disorders, part H

288*

AA1

FDA human cardiac rate rhythnm disorders, control

1632*

AA2

FDA human cardiac rate rhythnm disorders, part A

612*

AA3

FDA human cardiac rate rhythnm disorders, part B

611*

AA4

FDA human cardiac rate rhythnm disorders, part C

611*

AA5

FDA human cardiac rate rhythnm disorders, part D

611*

AB8

FDA human cardiac palpitations, control

1632*

AB9

FDA human cardiac palpitations, part A

478*
AC1

FDA human cardiac palpitations, part B

478*

A08

FDA human cardiac conduction disorders, control

1632*

A09

FDA human cardiac conduction disorders, part A

336*

A10

FDA human cardiac conduction disorders, part B

336*

A11

FDA human cardiac conduction disorders, part C

336*

A12

FDA human cardiac conduction disorders, part D

336*

A13

FDA human cardiac conduction disorders, part E

336*

A14

FDA human cardiac conduction disorders, part F

336*

A15

FDA human cardiac conduction disorders, part G

336*

A29

FDA human cardiac coronary artery dissorder, control

1632*

A30

FDA human cardiac coronary artery dissorder, part A

587*

A31

FDA human cardiac coronary artery dissorder, part B

587*

A32

FDA human cardiac coronary artery dissorder, part C

586*

A33

FDA human cardiac coronary artery dissorder, part D

586*

A46

FDA human cardiac electrocardiogram dissorders, control

1632*

A47

FDA human cardiac electrocardiogram dissorders, part A

416*

A48

FDA human cardiac electrocardiogram dissorders, part B

416*

A49

FDA human cardiac electrocardiogram dissorders, part C

415*

A50

FDA human cardiac electrocardiogram dissorders, part D

415*

A51

FDA human cardiac electrocardiogram dissorders, part E

415*

A52

FDA human cardiac electrocardiogram dissorders, part F

415*

A66

FDA human cardiac heart failure disorders, control

1632*

A67

FDA human cardiac heart failure disorders, part A

491*

A68

FDA human cardiac heart failure disorders, part B

491*

A69

FDA human cardiac heart failure disorders, part C

490*

A70

FDA human cardiac heart failure disorders, part D

490*

A71

FDA human cardiac heart failure disorders, part E

490*

A87

FDA human cardiac myocardial disorders, control

1632*

A88

FDA human cardiac myocardial disorders, part A

289*

A89

FDA human cardiac myocardial disorders, part B

289*

A90

FDA human cardiac myocardial disorders, part C

289*

A91

FDA human cardiac myocardial disorders, part D

289*

A92

FDA human cardiac myocardial disorders, part E

289*

A93

FDA human cardiac myocardial disorders, part F

289*

A94

FDA human cardiac myocardial disorders, part G

289*

A95

FDA human cardiac myocardial disorders, part H

288*

AA1

FDA human cardiac rate rhythnm disorders, control

1632*

AA2

FDA human cardiac rate rhythnm disorders, part A

612*

AA3

FDA human cardiac rate rhythnm disorders, part B

611*

AA4

FDA human cardiac rate rhythnm disorders, part C

611*

AA5

FDA human cardiac rate rhythnm disorders, part D

611*

AB8

FDA human cardiac palpitations, control

1632*

AB9

FDA human cardiac palpitations, part A

478*
AC1

FDA human cardiac palpitations, part B

478*

AC2

FDA human cardiac palpitations, part C

478*

AC3

FDA human cardiac palpitations, part D

477*

AC4

FDA human cardiac palpitations, part E

477*

AD7

FDA human cardiac arrhythmia disorders, control

1632*

AD8

FDA human cardiac arrhythmia disorders, part A

566*

AD9

FDA human cardiac arrhythmia disorders, part B

566*

AE1

FDA human cardiac arrhythmia disorders, part C

565*

AE2

FDA human cardiac arrhythmia disorders, part D

565*

AH3

FDA human cardiac QT-prolongation, control

1632*

AH4

FDA human cardiac QT-prolongation, part A

397*

AH5

FDA human cardiac QT-prolongation, part B

397*

AH6

FDA human cardiac QT-prolongation, part C

397*

AH7

FDA human cardiac QT-prolongation, part D

397*

AH8

FDA human cardiac QT-prolongation, part E

397*

AH9

FDA human cardiac QT-prolongation, part F

397*

AP6

FDA human cardiac Tachycardia, control

1632*

AP7

FDA human cardiac Tachycardia, part A

486*

AP8

FDA human cardiac Tachycardia, part B

486*

AP9

FDA human cardiac Tachycardia, part C

486*

AQ1

FDA human cardiac Tachycardia, part D

485*

AQ2

FDA human cardiac Tachycardia, part E

485*

AQ3

FDA human cardiac bradycardia, control

1632*

AQ4

FDA human cardiac bradycardia, part A

299*

AQ5

FDA human cardiac bradycardia, part B

299*

AQ6

FDA human cardiac bradycardia, part C

299*

AQ7

FDA human cardiac bradycardia, part D

299*

AQ8

FDA human cardiac bradycardia, part E

298*

AQ9

FDA human cardiac bradycardia, part F

298*

AR1

FDA human cardiac bradycardia, part G

298*

AR2

FDA human cardiac bradycardia, part H

298*

AR3

FDA human cardiacmyocardial infarction, control

1632*

AR4

FDA human cardiacmyocardial infarction, part A

332*

AR5

FDA human cardiacmyocardial infarction, part B

332*

AR6

FDA human cardiacmyocardial infarction, part C

332*

AR7

FDA human cardiacmyocardial infarction, part D

332*

AR8

FDA human cardiacmyocardial infarction, part E

332*

AR9

FDA human cardiacmyocardial infarction, part F

331*

AS1

FDA human cardiacmyocardial infarction, part G

331*
AU5

FDA human cardiac Torsade, control

1632*

AU6

FDA human cardiac Torsade, part A

341*

AU7

FDA human cardiac Torsade, part B

341*

AU8

FDA human cardiac Torsade, part C

340*

AU9

FDA human cardiac Torsade, part D

340*

AV1

FDA human cardiac Torsade, part E

340*

AV2

FDA human cardiac Torsade, part F

340*

AV3

FDA human cardiac Torsade, part G

340*

* - New in 2008

Click to request information

[ Home ] [ Up ] [ Feedback ] [ Contents ] [ Search ] [ Contacts ] [ Publications ] [ FAQ ] [ Support ] [ About Us ]

Send mail to saiakhov@multicase.com with questions or comments about this web site.
Copyright © 2010 Multicase Inc
Last modified: 01/04/10

MultiCASE MC4PC-based computational toxicology estimations are intended to be used as part of a weight of evidence approach for hazard and risk assessment that includes laboratory experimental data. Computational toxicology predictions are not intended as a substitute for appropriate animal or clinical studies. Results obtained with certain MC4PC software modules should be regarded as preliminary and subject to change.